A series of conformationally restricted dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) hybrids, which combined the structural features of C6-α-methylbenzyl-thio-DABOs (α-methyl-S-DABOs) and C6-α-cyanobenzyl-thio-DABOs (CN-S-DABOs), has been synthesized and biologically evaluated for their anti-HIV activity against wild-type HIV-1 strain IIIB, double RT mutant (K103N + Y181C) strain RES056 and HIV-2 strain ROD in MT-4 cell cultures. Most of these compounds exhibited inhibitory activity (wild-type) within the range of EC50 values from micromolar to nanomolar. Among them, compound 1s displayed the highest anti-HIV-1 activity with an EC50 value of 91 nM and a selectivity index (SI) of 548, which was more potent than zalcitabine and comparable to nevirapine and delavirdine in the same assay. The HIV-1 reverse transcriptase inhibitory (RT) assay confirmed that these conformationally restricted S-DABO hybrids targeted HIV-1 RT. The preliminary structure–activity relationship (SAR) and molecular docking analysis of this new series of conformationally constrained CN-S-DABO hybrids were also investigated.
一系列构象受限的二氢烷基
硫代苯甲基氧
嘧啶(S-
DABO)杂化物已被合成并对其抗HIV活性进行了
生物学评价,这些杂化物结合了C6-α-甲基苯甲基
硫代
DABO(α-甲基-S-
DABO)和C6-α-
氰基苯甲基
硫代
DABO(CN-S-
DABO)的结构特征。这些化合物在
MT-4
细胞培养中对野生型HIV-1株IIIB、双重逆转录酶突变体(K103N + Y181C)株RES056和HIV-2株ROD进行了抗HIV活性评估。大多数化合物表现出抑制活性(野生型),其
EC50值范围从微摩尔到纳摩尔。其中,化合物1s显示出最高的抗HIV-1活性,其
EC50值为91 nM,选择性指数(SI)为548,比
扎西他滨更有效,与
奈韦拉平和
地拉韦啶在同一测定中相当。HIV-1逆转录酶抑制(RT)测定证实,这些构象受限的S-
DABO杂化物靶向HIV-1逆转录酶。还对这一新系列构象约束的CN-S-
DABO杂化物的初步结构-活性关系(
SAR)和分子对接分析进行了研究。